Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

Abstract Objectives Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms...

Ful tanımlama

Detaylı Bibliyografya
Asıl Yazarlar: Guangjian Yang, Di Ma, Haiyan Xu, Lu Yang, Junling Li, Puyuan Xing, Xuezhi Hao, Yan Wang
Materyal Türü: Makale
Dil:English
Baskı/Yayın Bilgisi: Wiley 2019-10-01
Seri Bilgileri:Cancer Medicine
Konular:
anaplastic lymphoma kinase inhibitor
crizotinib
crizotinib continuation beyond progressive disease
non‐small cell lung cancer
treatment duration
Online Erişim:https://doi.org/10.1002/cam4.2420

Internet

https://doi.org/10.1002/cam4.2420

Benzer Materyaller